enoxaparin

enoxaparin is a widely used anticoagulant medication classified as a low molecular weight heparin. It is primarily employed for the prevention and treatment of venous thromboembolism, including conditions like deep vein thrombosis and pulmonary embolism. The drug is also a standard component of therapy for acute coronary syndrome and is used to prevent clotting during procedures such as hemodialysis and certain types of surgery.

Medical uses

The primary medical applications involve prophylaxis and treatment of thrombotic events. It is a cornerstone for preventing deep vein thrombosis in patients undergoing major orthopedic surgery, such as total hip replacement or total knee arthroplasty. In the setting of acute coronary syndrome, including unstable angina and non-ST-elevation myocardial infarction, it is used alongside antiplatelet agents like aspirin and clopidogrel. Furthermore, it is indicated for the treatment of established deep vein thrombosis and pulmonary embolism, often as a bridge to longer-term oral anticoagulation with agents like warfarin. It is also utilized in medical patients at high risk for thromboembolism and to maintain patency of intravenous catheters during extracorporeal circulation.

Adverse effects

The most significant risk associated with its use is bleeding, which can range from minor ecchymosis at the injection site to life-threatening intracranial hemorrhage or gastrointestinal bleeding. A serious, albeit rare, complication is heparin-induced thrombocytopenia, an immune-mediated reaction that can paradoxically lead to arterial thrombosis. Other potential adverse effects include elevated liver enzymes, osteoporosis with long-term use, and local reactions such as skin necrosis at the injection site. The risk of bleeding is increased in patients with renal impairment, the elderly, and those concurrently taking other antithrombotic medications.

Pharmacology

As a low molecular weight heparin, it acts by potentiating the activity of antithrombin III, a natural inhibitor of coagulation factors, primarily Factor Xa and, to a lesser degree, thrombin. Its molecular weight, averaging 4500 daltons, is derived from the controlled chemical or enzymatic depolymerization of unfractionated heparin. This results in a more predictable pharmacokinetic profile, with higher bioavailability after subcutaneous injection and a longer plasma half-life compared to unfractionated heparin. It exhibits less binding to platelet factor 4 and endothelial cells, contributing to a more predictable dose response and a lower risk of heparin-induced thrombocytopenia. Monitoring of anti-factor Xa activity is recommended in specific populations, such as pregnant women or those with severe renal failure.

History

The development of low molecular weight heparins, including this agent, originated from research in the 1970s and 1980s aimed at improving upon the limitations of unfractionated heparin. Scientists at Institut Choay in France played a key role in its early development through a process of beta-elimination depolymerization. It received approval from the Food and Drug Administration in the United States in 1993, marketed under the brand name Lovenox by the pharmaceutical company Sanofi. Its introduction represented a significant advance in anticoagulation therapy, offering the convenience of once- or twice-daily subcutaneous administration without the need for routine monitoring of the activated partial thromboplastin time.

Society and culture

It is available globally under various brand names, including Lovenox and Clexane, and as numerous generic versions. Its high cost has been a subject of discussion within healthcare systems, though the availability of generics has increased access. The drug is listed on the World Health Organization Model List of Essential Medicines, underscoring its importance in basic health systems. Its use is governed by specific guidelines from major medical bodies like the American College of Chest Physicians and the American Heart Association. The development and marketing of the drug have involved significant legal and patent disputes between pharmaceutical companies, including notable litigation involving Sanofi and Amphastar Pharmaceuticals.

Category:Anticoagulants Category:Heparins Category:World Health Organization essential medicines